Immuneonco Biopharmaceuticals (shanghai) Inc Class H · HKEX:1541
Immuneonco Biopharmaceuticals (shanghai) Inc Class H — J.P. Morgan Healthcare Conference 2026
36 slides from Immuneonco Biopharmaceuticals (shanghai) Inc Class H's conference presentation, January 2026
Slide 1: Corporate Presentation
Corporate Presentation Jan 2026
Slide 2: Disclaimer
Disclaimer THIS DOCUMENT OR THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO AND DOES NOT CONSTITUTE ANY OFFER OR INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT OF ANY OFFER FOR SUBSCRIPTION, PURHCASE OR SALE OF ANY SECURITIES, NOR SHALL ANY PART OF THIS DOCUMENT FORM THE BASIS OF OR BE RE
Slide 3: Table of Contents
Table of Contents Company Overview Timdarpacept (IMM01, SIRPα-Fc) Amulirafusp alfa (IMM0306, CD47×CD20) Palverafusp alfa (IMM2510, VEGF×PD-L1) 3
Slide 4: Company Overview
OY, Company Overview
Slide 5: Key Milestones
Key Milestones • 30 issued patents • Steady team with 10+ years coordination • 31 pending patent applications • 31 IND approvals from the NMPA and the FDA • 12 ongoing clinical programs 2015-2020 2021-2022 2023 2024 2025 • 2015: ImmuneOnco was IMM01: IMM2510+ IMM27M in IMM01: • SLE& NMOSD dosed firs
Slide 6: Integrated proprietary R&D platform
Integrated proprietary R&D platform Efficiently Conduct Screening Optimize Molecule Structure Cost-effectively Manufacture Next-generation Innovative and Druggability Analysis Design High-quality Drug In-house Oncology Therapies Target Selection and High-throughput CMC and IND-enabling Validation Dr
Slide 7: Comprehensive Pipeline in Oncology
Comprehensive Pipeline in Oncology Target IND/IND- Phase III/ Commercial Program (1) Indication(s) Discovery Preclinical Phase Ia/I Phase Ib/II Current Status / Upcoming Milestone (Modality) Enabling Pivotal Rights IMM01 (timdarpacept) CD47 + Azacitidine (SIRPα-Fc fusion 1L MDS(2) China (NMPA) Recei
Slide 8: Comprehensive Pipeline in non-Oncology
Comprehensive Pipeline in non-Oncology Target IND/IND- Phase III/ Commercia Program (1) Indication(s) Discovery Preclinical Phase Ia/I Phase Ib/II Current Status / Upcoming Milestone (Modality) Enabling Pivotal l Rights IMM0306 CD47xCD20 FPI in October 2024, completed the first and second cohort SLE
Slide 9: Timdarpacept (IMM01, SIRPα-Fc)
Timdarpacept (IMM01, SIRPα-Fc) Phase III in chronic myelomonocytic leukemia (CMML); Potential earliest interim data readout by Q4 2026.
Slide 10: IMM01 (Timdarpacept, SIRPα-Fc) Highlight
IMM01 (Timdarpacept, SIRPα-Fc) Highlight • 1L CMML - Phase II (In combo with azacitidine): IMM01 CRR = 27.3%, mPFS = 17.8 months (ASCO 2025) SIRPα Blocking “Don’t eat domain me” signal via interrupting CD47- SIRPα interaction • 1L CMML - Phase III (In combo with azacitidine): Activating “Eat me” Int
Slide 11: Overview and Competitive Advantage of IMM01 (Timdarpacept)
Timdarpacept (IMM01) Overview and Competitive Advantage of IMM01(Timdarpacept) In Vivo Efficacy of IMM01 is Dependent on Effective Fc Function (HL-60 xenograft model) IMM01 Full activation of macrophages SIRPα Blocking “Don’t eat me” IMM01 IMM01M domain signal via interrupting CD47 CD47-SIRPα intera
Slide 12: Timdarpacept (IMM01) Has Strong Potentials in treating atherosclerosis
Timdarpacept (IMM01) Has Strong Potentials in treating atherosclerosis Our CD47-targeted IMM01 presents a strong potential in treating atherosclerosis CD47 is highly expressed in human atherosclerotic plaque By blocking the CD47 signal, macrophages can phagocytose the atherosclerotic plaque in rat v
Slide 13: Timdarpacept (IMM01) – Animal study Results in Atherosclerosis
Timdarpacept (IMM01) – Animal study Results Demonstrated Strong Potential in Treating Atherosclerosis Representative gross pictures of the left common carotid artery HE and Masson staining of left carotid artery transverse section Red arrow: hemorrhage site Statistically analysis of the results from
Slide 14: IMM0306 (Amulirafusp alfa, CD47×CD20 mAb-Trap)
IMM0306 (Amulirafusp alfa, CD47×CD20 mAb-Trap) Phase III - 3L follicular lymphoma, Q1 2026 start Phase Ib/II - Systemic lupus erythematosus
Slide 15: IMM0306 (Amulirafusp alfa, CD20xCD47 mAb-Trap) Highlight
IMM0306 (Amulirafusp alfa, CD20xCD47 mAb-Trap) Highlight • R/R-FL, Phase II (In combo with lenalidomide): IMM0306 ORR = 91.2%, CRR = 67.6% (ASH 2025) SIRPα-D1 • R/R-FL, Phase III (In combo with lenalidomide): Anti-CD20 FPI is expected by end of Jan 2026 IgG1 with Enhanced ADCC • SLE, Phase Ib/II (SR
Slide 16: IMM0306 (Amulirafusp alfa, CD47×CD20)
IMM0306 (Amulirafusp alfa, CD47×CD20) 1st CD47 and CD20 Dual-targeting Bispecific to Enter into the Clinical Stage Globally Overview Mechanism of Action IMM0306 Molecule Structure Full macrophage activation IgG4 CD47 mAb SIRPα-D1 SIRPα “Don’t eat me” blocked “Eat me” signal inactive Improved ADCP an
Slide 17: IMM0306 Phase I/II - Study Design
IMM0306 (Amulirafusp alfa, CD47×CD20) Phase I/II - Study Design This is an open-label, multicenter phase I/II study in patients with R/R B-cell NHL (NCT05771883). • Administration • The recommended Phase II dose (RP2D): 1.6 mg/kg Amulirafusp alfa in combination with 20 mg lenalidomide. • Amulirafusp
Slide 18: IMM0306 Phase I/II - Baseline Characteristic
IMM0306 (Amulirafusp alfa, CD47×CD20) Phase I/II - Baseline Characteristic Baseline Characteristic Patients (N=38) Age, years Median (range) 54 (32-74) • As of July 10, 2025, 38 patients with FL Gender, n (%) Male 22 (57.9) were enrolled in phase II. Female 16 (42.1) ECOG PS, n (%) 0 18 (47.4) • The
Slide 19: IMM0306 Phase I/II - Efficacy
IMM0306 (Amulirafusp alfa, CD47×CD20) Phase I/II - Efficacy Patients (N=34) ORR, n (%) 31 (91.2) CR, n (%) 23 (67.6) PR, n (%) 8 (23.5) PFS, months, median (95% CI) NR (NR, NR) 6-month rate,% 91.2 (75.1, 97.1) Among 18 CD20-refractory patients, the CR rate, ORR and 6-month PFS rate were 66.7%, 88.9%
Slide 20: IMM0306 Phase I/II - Safety
IMM0306 (Amulirafusp alfa, CD47×CD20) Phase I/II - Safety Patients The safety-evaluable population included 47 FL Overview of TRAE, n(%) (N=47) patients, of whom 9 patients were in phase I and 38 All grade TRAE 47 (100.0) patients were in phase II. ≥ G3 TRAE 44 (93.6) • 44 (93.6%) patients had Grade
Slide 21: IMM0306 Phase I/II - Conclusion
IMM0306 (Amulirafusp alfa, CD47×CD20) Phase I/II - Conclusion Amulirafusp alfa in combination with lenalidomide showed a high rate of response and a well-tolerated safety profile in patients with R/R FL. ➢Promising anti-tumor efficacy - ORR 91.2%, CR rate 67.6% - The median PFS was not reached and 6
Slide 22: IMM0306 - Potential in Autoimmune Diseases
IMM0306 (Amulirafusp alfa, CD47×CD20) - Potential in Autoimmune Diseases IND Approved in China IND submitted IND planned in US & China Systemic lupus Subcutaneous formulation erythematosus (SLE) for SLE Phase Ib China IND submitted Multiple sclerosis (MS) China: Phase II US: Phase Ib/II Neuromyeliti
Slide 23: IMM0306 - SLE Phase Ib Trial Design
IMM0306 (Amulirafusp alfa, CD47×CD20) - SLE Phase Ib Trial Design Screening Treatment Period (52W) 4W W1-W24 (Primary Treatment Period） W25-W52 (Extension Treatment Period) 0.8 mg/kg N=8 1.2 mg/kg Safety: AE and SAE incidence N = 11 PK parameters: Cmax , tmax, t1/2, AUC, CL,etc. 1.6 mg/kg Efficacy:
Slide 24: Amulirafusp alfa is Well Tolerated in SLE Patients
Amulirafusp alfa is Well Tolerated in SLE Patients Amulirafusp alfa Total Overview of TRAEs，n(%) 0.8mg/kg 1.2mg/kg (N=11) (N=19*) (N=8*) All grade TRAE 5(62.5) 9(81.8) 14(73.7) ≥ G3 TRAE 1(12.5) 1(9.1) 2(10.5) TRAE leading to dose reduction 0 0 0 Treatment-related SAE 0 0 0 TRAE leading to withdrawa
Slide 25: Amulirafusp alfa Shows Rapid, Dose-Dependent SLEDAI-2K Improvement
Amulirafusp alfa Shows Rapid, Dose-Dependent SLEDAI-2K Improvement SRI-4 Response Proportion of patients with ≥ 4 points reduction from baseline in SLEDAI-2K score 100 1.2mg/kg 0.8mg/kg Over time 12W / 24W 75 100 100 %Patients 50 80 75 %Patients %Patients 60 25 50 40 1.2mg/kg 25 0 20 0.8mg/kg 12W 24
Slide 26: Situation of Arthritis, Rash, Alopecia and Vasculitis are Improved
Amulirafusp alfa - Situation of Arthritis, Rash, Alopecia and Vasculitis are Improved Arthritis Rash Number of patients with arthritis 8 8 Number of patients with rash 7 7 6 6 5 5 4 4 3 3 2 2 1 dose dose 1 dose dose 0 0 BL 4W 8W 12W 16W 20W 24W 28W 32W 36W 40W BL 4W 8W 12W 16W 20W 24W 28W 32W 36W 40
Slide 27: Efficient and Sustained B-cell Depletion with Immune Reconstitution
Amulirafusp alfa - Efficient and Sustained B-cell Depletion with Immune Reconstitution Observed CD19+ B cell Memory B (CD27+IgD-） 400 40 Pat.1 200 Pat.2 Pat.3 In Patients 5, 6, 8, 9 and 10, B-lineage CD19+ B cell count cell/l Memory B cell count cell/l 100 30 Pat.4 Pat.5 Pat.6 cells rebounded betw
Slide 28: Amulirafusp alfa - Shows Best-in-disease Potential in SLE
Amulirafusp alfa - Shows Best-in-disease Potential in SLE Mosunetuzuma Amulirafusp alfa Telitacicept3 Belimumab4 b2 Target CD47xCD20 CD3xCD20 BLyS, APRIL BLyS Dose 0.8 mg/kg 1.2 mg/kg 15/45/60 mg 160 mg 10 mg/kg 71% 80% 66.7%2.1 67% 43% SRI-4 response (5/7) (4/5) (4/6) (N=167) (N=273) Week24 1 Week2
Slide 29: Palverafusp alfa (IMM2510, VEGF × PD-L1)
Palverafusp alfa (IMM2510, VEGF × PD-L1) Regained global rights Phase III – IO-treated NSCLC, Q2 2026 start EOP2 with authority for consolidation therapy of lung cancer
Slide 30: Palverafusp alfa (VEGFxPD-L1, mAb-Trap) Highlight
Palverafusp alfa (VEGFxPD-L1, mAb-Trap) Highlight • SQ-NSCLC, IO-failed, Phase II (Monotherapy): ORR = 35.3%, mPFS = 9.4 months (WCLC 2025) VEGR1-D2 • Phase III for sq-NSCLC: PD-L1 Initiation planned for Q2 2026 IgG1 Enhanced ADCC • Neoadjuvant therapy of sq-NSCLC, Phase II: IND approved • Neoadjuva
Slide 31: Palverafusp alfa (IMM2510) Key Competitor Landscape
Palverafusp alfa(IMM2510) (VEGF × PD-L1) Key Competitor Landscape IMM2510 PM8002 AK112 SSGJ-707 (ImmuneOnco / Instil (BioNTech) (Akeso / Summit) ( 3SBio/ Pfizer） Bio) VEGF-A, VEGF-B, VEGF binding VEGF-A VEGF-A VEGF-A PlGF PD-1 or PD-L1 PD-L1 PD-L1 PD-1 PD-1 ADCC Enhanced ADCC None None None VEGR1-D2
Slide 32: Efficacy comparison vs other VEGFxPD(L)-1 in NSCLC
Efficacy comparison vs other VEGFxPD(L)-1 in NSCLC Palverafusp alfa Palverafusp alfa Pumitamig Pumitamig Ivonescimab2 (IMM2510)1 (IMM2510)1 (BNT327)3 (BNT327)3 Tumor type NSCLC NSCLC NSCLC NSCLC NSCLC EGFR/ALK/ROS Subtype All squamous EGFR-mut EGFR/ALK wiletype wildtype 10-30mg/kg Dosage 3-20mg/kg Q
Slide 33: Safety comparison vs other VEGFxPD(L)-1
Safety comparison vs other VEGFxPD(L)-1 Palverafusp alfa (IMM2510) Ivonescimab Pumitamig (BNT327) Type Phase I (n=150) 3 Phase Ia (n=51)1 Phase Ia (n=80) 2 Patient Advanced solid tumor Advanced solid tumor Advanced solid tumor TRAEs – all 92.7% 74.5% 77.5% TRAEs – grade 3 and above 22.7% 27.5% 22.5%
Slide 34: Efficacy comparison of monotherapy in IO-treated NSCLC
Efficacy comparison of monotherapy in IO-treated NSCLC, vs PD-L1 ADC, PD1xIL2 Company ImmuneOnco1 Henlius2 Innovent 3 Product Palverafusp alfa （IMM2510） HLX43 IBI363 Target (Modality) PD-L1 /VEGF (Bispecific) PD-L1 ADC PD-1 /IL-2α (Bispecific) Clinical ID NCT05972460 NCT06115642 NCT05460767 Late-sta
Slide 35: Safety comparison of monotherapy in IO-treated NSCLC
Safety comparison of monotherapy in IO-treated NSCLC, vs PD-L1 ADC, PD1xIL2 IMM2510 1 HLX43 2 IBI363 3 IBI363 3 (3mg/kg Q3W；6mg/kg Q3W ； Category Phase I (2.0mg/kg；2.5 Phase I (1mg/kg Q2W ;1.5mg/kg Q3W） Phase I (3mg/kg-Q3W） 10mg/kg Q3W; 20 mg/kg Q3W) mg/kg）(n=56)1 （n=62) 2 （n=57) 2 Phase I (n=23) 3
Slide 36: Thank you!
Thank you!
ImmuneOnco Biopharmaceuticals (Shanghai) — J.P. Morgan Healthcare Conference 2026 on 6ix